参考资料:
[1]Herman, M.A., Metabolic liver disease — what’s in a name? Nature Reviews Endocrinology, 2020.
[2]Jelena Todoric et al. (2020) Fructose stimulated de novo lipogenesis is promoted by inflammation. Nature Metabolism
[3]Giovanni Targher, et al., (2021). Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. The Lancet Gastroenterology & Hepatology
[4]非酒精性脂肪性肝病防治指南(2018更新版)[J].传染病信息,2018,31(05):393-402+420.
[5]Parthasarathy, G. et al. “Pathogenesis of Nonalcoholic Steatohepatitis: An Overview.” Hepatology Communications 4 (2020): 478 - 492.
[6]Younossi, Z. et al. “Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.” Clinical Gastroenterology & Hepatology 17 (2019): 748–755.e3.
[7]Younossi, Z. et al. “Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.” Hepatology 69 (2019): n. pag.
[8]Younossi, Z. et al. “Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.” Transplantation (2019): n. pag.
[9]Harrison, S. et al. “NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.” Hepatology (Baltimore, Md.) 71 (2019): 1198 - 1212.
[10]Choi, Hannah S. J. et al. “Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B.” Hepatology 71 (2019): n. pag.
[11]Diehl, A. and Christopher Day. “Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.” The New England Journal of Medicine 377 (2017): 2063–2072.
[12]Kim, D. et al. “Predictors of nonalcoholic steatohepatitis and significant fibrosis in non‐obese nonalcoholic fatty liver disease.” Liver International 39 (2019): 332 - 341.
[13]Younossi, Z. et al. “Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.” Hepatology 68 (2018): n. pag.
39健康网(www.39.net)专稿,未经书面授权请勿转载。
擅长领域:擅长普外肿瘤(胃肿瘤、结直肠肿瘤、乳腺肿瘤、甲状腺肿瘤、腹腔及后腹膜肿瘤、肝胆胰肿瘤、全身体表肿瘤);肛肠疾病(严重环庤、脱肛、直肠脱垂、直肠息肉、便秘、肛周脓肿、肛瘘、肛裂、肛门狭窄及肛门成形);各种急腹症(急性消化道穿孔、出血,肠梗阻,急性胰腺炎,胆管炎,破伤风等)的临床诊治和科研、教学。尤其在低位直肠癌全系膜前切除超低位机械性保肛术(300多例)、机械性吻合技术在消化道重建术中的临床运用研究(3000多例)、环痔PPH术已达到国内先进水平,并先后两次获暨南大学医学院级和卫生厅科技成果奖。
擅长领域:在胃癌根治术、全直肠系膜切除、低位保留肛门和保护性功能的直肠癌根治术、结肠“J” 型贮袋重建直肠术等方面有深入的研究和丰富的经验;对于胰腺疾病、腹膜后肿瘤、食道癌、食道良性疾病、结直肠息肉及息肉病及胃肠道间质瘤等有丰富的诊治经验;熟练应用腹腔镜及消化道内镜对胃肠道疾病进行诊断和治疗。
擅长领域:各部位胃癌D2标准化根治手术、结肠癌根治、直肠癌根治手术。尤其一直从事炎症性疾病如克罗恩(俗称克隆病)病和溃疡性结肠炎的基础和临床研究,对肠内外营养、各种复杂性肠瘘的处理经验丰富。